USF-LVHN SELECT
Advances in Hemophilia A Management.
Publication/Presentation Date
8-1-2022
Abstract
Hemophilia A is an inherited insufficiency of Factor VIII (FVIII), one of the critical clotting factors. The gold standard for the management of moderate-to-severe hemophilia A is prophylaxis using regular replacement therapy with clotting factor concentrates. Compared with conventional treatment, extended half-life products reduce the burden of frequent factor replacement injections. Of note, up to 30% of patients with hemophilia A receiving prophylactic factor infusions develop "inhibitors," neutralizing anti-FVIII autoantibodies. Therapeutic options for patients with hemophilia A and inhibitors include the immune tolerance induction (ie, eradication of inhibitors) and the management of acute bleeds with bypassing agents and/or emicizumab. Emicizumab is a biphasic monoclonal antibody mimicking activated FVIII, approved for patients with hemophilia A with/without inhibitors. Gene therapy is an emerging therapy for hemophilia A, essentially curing patients with hemophilia A or transforming them to a milder phenotype by establishing continuous endogenous expression of FVIII after one-time treatment.
Volume
69
Issue
1
First Page
133
Last Page
147
ISSN
1878-1926
Published In/Presented At
Cho, S., Perry, A. M., Cheng, A. M., Wang, C., & Rico, J. F. (2022). Advances in Hemophilia A Management. Advances in pediatrics, 69(1), 133–147. https://doi.org/10.1016/j.yapd.2022.03.009
Disciplines
Medical Education | Medicine and Health Sciences
PubMedID
35985706
Department(s)
USF-LVHN SELECT Program, USF-LVHN SELECT Program Students
Document Type
Article